피부 및 연조직 감염에서의 항생제 내성 및 최신 치료

키워드

참고문헌 (100)

1. Bisno AL, "Streptococcal infections of skin and soft tissues", N Engl J Med, 334, pp.240~245 (1996)
2. Chartier C, "Erysipelas: an update", Int J Dermatol, 35, pp.779~781 (1996)
3. Bonnetblanc JM, "Erysipelas: recognition and management", Am J Clin Dermatol, 4, pp.157~163 (2003)
4. Krasagakis K, "Analysis of epidemiology, clinical features and management of erysipelas", Int J Dermatol, 49, pp.1012~1017 (2010)
5. Dupuy A, "Risk factors for erysipelas of the leg (cellulitis): case-control study", BMJ, 318, pp.1591~1594 (1999)
6. Cox NH, "Oedema as a risk factor for multiple episodes of cellulitis", erysipelas of the lower leg: a series with community follow-up, 2006, pp.155, 947~950
7. Mokni M, "Risk factors for erysipelas of the leg in Tunisia: a multicenter case-control study", Dermatology, 212, pp.108~112 (2006)
8. Bartholomeeusen S, "Epidemiology and comorbidity of erysipelas in primary care", Dermatology, 215, pp.118~122 (2007)
9. Dan M, "Incidence of erysipelas following venectomy for coronary artery bypass surgery", Infection, 15, pp.107~108 (1987)
10. Hinten F, "Risk factors for short- and long-term complications after groin surgery in vulvar cancer", Br J Cancer, 105, pp.1279~1287 (2011)
11. Chartier C, "Erysipelas", Int J Dermatol, 29, pp.459~467 (1990)
12. Bernard P, "Streptococcal cause of erysipelas and cellulitis in adults: a microbiologic study using a direct immunofluorescence technique", Arch Dermatol, 125, pp.779~782 (1989)
13. Eriksson B, "Erysipelas: clinical and bacteriologic spectrum and serological aspects", Clin Infect Dis, 23, pp.1091~1098 (1996)
14. Jung HS, "Clinical features of infections caused by streptococcus pyogenes in children and their antimicrobial susceptibility", Korean J Infect Dis, 30, pp.419~425 (1998)
15. Gracia M, "Antimicrobial susceptibility of Streptococcus pyogenes in Central, Eastern, and Baltic European Countries, 2005 to 2006: the cefditoren surveillance program", Diagn Microbiol Infect Dis, 64, pp.52~56 (2009)
16. Torres RS, "Group a streptococcus antibiotic resistance in southern Brazil: a 17-year surveillance study", Microb Drug Resist, 17, pp.313~319 (2011)
17. Kilburn SA, "Interventions for cellulitis and erysipelas", Cochrane Database Syst Rev 2010:CD004299, ~ (2010)
18. Jorup-Rönström C, "The course, costs and complications of oral versus intravenous penicillin therapy of erysipelas", Infection, 12, pp.390~394 (1984)
19. Stevens DL, "Practice guidelines for the diagnosis and management of skin and soft-tissue infections", Clin Infect Dis, 41, pp.1373~1406 (2005)
20. Bernard P, "Roxithromycin versus penicillin in the treatment of erysipelas in adults: a comparative study", Br J Dermatol, 127, pp.155~159 (1992)
21. Jones ME, "Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy", Int J Antimicrob Agents, 22, pp.406~419 (2003)
22. Richter SS, "Increasing telithromycin resistance among Streptococcus pyogenes in Europe", J Antimicrob Chemother, 61, pp.603~611 (2008)
23. Critchley IA, "Antimicrobial susceptibilities of Streptococcus pyogenes isolated from respiratory and skin and soft tissue infections: United States LIBRA surveillance data from 1999", Diagn Microbiol Infect Dis, 42, pp.129~135 (2002)
24. Katz KC, "Emergence of macrolide resistance in throat culture isolates of group a streptococci in Ontario, Canada, in 2001", Antimicrob Agents Chemother, 47, pp.2370~2372 (2003)
25. Green M, "Reemergence of macrolide resistance in pharyngeal isolates of group a streptococci in southwestern Pennsylvania", Antimicrob Agents Chemother, 48, pp.473~476 (2004)
26. Richter SS, "Macrolideresistant Streptococcus pyogenes in the United States, 2002-2003", Clin Infect Dis, 41, pp.599~608 (2005)
27. Green MD, "Multicentre surveillance of the prevalence and molecular epidemiology of macrolide resistance among pharyngeal isolates of group A streptococci in the USA", J Antimicrob Chemother, 57, pp.1240~1243 (2006)
28. Michos AG, "Macrolide resistance in Streptococcus pyogenes: prevalence, resistance determinants, and emm types", Diagn Microbiol Infect Dis, 64, pp.295~299 (2009)
29. 고은하, "2004년 진주지역에서 분리된 Streptococcus pyogenes의 Erythromycin 내성률 감소", 대한임상미생물학회지, 9(1), pp.51~57 (2006), 대한임상미생물학회
30. 어영, "Macrolide Resistance Trends in β-Hemolytic Streptococci in a Tertiary Korean Hospital", Yonsei Medical Journal, 48(5), pp.773~778 (2007), 연세대학교의과대학
31. 고은하, "2006년 진주지역 초등학생에서 분리된 Streptococcus pyogenes의 T 항원형과 emm 유전자형 및 항생제 내성", 대한임상미생물학회지, 12(1), pp.6~10 (2009), 대한임상미생물학회
32. 고은하, "Decline in Erythromycin Resistance in Group A Streptococci from Acute Pharyngitis due to Changes in the emm Genotypes Rather Than Restriction of Antibiotic Use", Annals of Laboratory Medicine, 30(5), pp.485~490 (2010), 대한진단검사의학회
33. 김의종, "Multicenter Study of Molecular Epidemiology and Antibiotic Resistance of Group A Streptococci in 2008-2009 in Korea", 대한임상미생물학회지, 14(3), pp.85~90 (2011), 대한임상미생물학회
34. Biedenbach DJ, "Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY antimicrobial surveillance program (1997-2004)", Diagn Microbiol Infect Dis, 55, pp.119~127 (2006)
35. 김재석, "국내 13개 의료기관에서 수집된 Staphylococcus aureus의 항균제 감수성 양상", Annals of Laboratory Medicine, 24(4), pp.223~229 (2004), 대한진단검사의학회
36. Hong HJ, "A clinical study on Staphylococcus aureus bacteremia", Korean J Med, 53, pp.359~370 (1997)
37. 박진용, "지역사회획득 메치실린 내성 황색포도알균 감염증의 임상적 특성과 위험인자 : 지역사회획득 메치실린 감수성 황색포도알균 감염증과 비교", Infection and Chemotherapy, 38(3), pp.109~115 (2006), 대한감염학회
38. Bergkvist PI, "Relapse of erysipelas following treatment with prednisolone or placebo in addition to antibiotics: a 1-year follow-up", Scand J Infect Dis, 30, pp.206~207 (1998)
39. Bergkvist PI, "Antibiotic and prednisolone therapy of erysipelas: a randomized, double blind, placebocontrolled study", Scand J Infect Dis, 29, pp.377~382 (1997)
40. Baddour LM, "Recurrent cellulitis after saphenous venectomy for coronary bypass surgery", Ann Intern Med, 97, pp.493~496 (1982)
41. Baddour LM, "Breast cellulitis complicating breast conservation therapy", J Intern Med, 245, pp.5~9 (1999)
42. Bouma J, "Recurrent acute leg cellulitis in patients after radical vulvectomy", Gynecol Oncol, 29, pp.50~57 (1988)
43. Brewer VH, "Risk factor analysis for breast cellulitis complicating breast conservation therapy", Clin Infect Dis, 31, pp.654~659 (2000)
44. Hook EW 3rd, "Microbiologic evaluation of cutaneous cellulitis in adults", Arch Intern Med, 146, pp.295~297 (1986)
45. Perl B, "Cost-effectiveness of blood cultures for adult patients with cellulitis", Clin Infect Dis, 29, pp.1483~1488 (1999)
46. Sigurdsson AF, "The etiology of bacterial cellulitis as determined by fine-needle aspiration", Scand J Infect Dis, 21, pp.537~542 (1989)
47. Chira S, "Staphylococcus aureus is the most common identified cause of cellulitis: a systematic review", Epidemiol Infect, 138, pp.313~317 (2010)
48. 이재영, "연조직염 환자에서 피부 생검 조직 배양을 통한 원인균 검출률 향상에 관한 연구", 대한피부과학회지, 45(2), pp.134~139 (2007), 대한피부과학회
49. Sadow KB, "Blood cultures in the evaluation of children with cellulitis", Pediatrics, 101, pp.E4~ (1998)
50. Newell PM, "Value of needle aspiration in bacteriologic diagnosis of cellulitis in adults", J Clin Microbiol, 26, pp.401~404 (1988)
51. Duvanel T, "Quantitative cultures of biopsy specimens from cutaneous cellulitis", Arch Intern Med, 149, pp.293~296 (1989)
52. Giordano PA, "Cefdinir vs. cephalexin for mild to moderate uncomplicated skin and skin structure infections in adolescents and adults", Curr Med Res Opin, 22, pp.2419~2428 (2006)
53. Hepburn MJ, "Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis", Arch Intern Med, 164, pp.1669~1674 (2004)
54. Grayson ML, "Once-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment of moderate-to-severe cellulitis in adults", Clin Infect Dis, 34, pp.1440~1448 (2002)
55. Muijsers RB, "Moxifloxacin in uncomplicated skin and skin structure infections", Drugs, 62, pp.967~973 (2002)
56. Parish LC, "Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections", Int J Clin Pract, 54, pp.497~503 (2000)
57. Ramirez-Ronda CH, "Comparative, double-blind study of oral ciprofloxacin and intravenous cefotaxime in skin and skin structure infections", Am J Med, 82, pp.220~223 (1987)
58. Fridkin SK, "Methicillinresistant Staphylococcus aureus disease in three communities", N Engl J Med, 352, pp.1436~1444 (2005)
59. Klevens RM, "Invasive methicillin-resistant Staphylococcus aureus infections in the United States", JAMA, 298, pp.1763~1771 (2007)
60. Hasty MB, "Cutaneous community-associated methicillin-resistant Staphylococcus aureus among all skin and soft-tissue infections in two geographically distant pediatric emergency departments", Acad Emerg Med, 14, pp.35~40 (2007)
61. Moran GJ, "Methicillinresistant S. aureus infections among patients in the emergency department", N Engl J Med, 355, pp.666~674 (2006)
62. Talan DA, "Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008", Clin Infect Dis, 53, pp.144~149 (2011)
63. Moran GJ, "Methicillin-resistant Staphylococcus aureus in communityacquired skin infections", Emerg infect Dis, 11, pp.928~930 (2005)
64. Liu C, "Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children", Clin Infect Dis, 52, pp.e18~e55 (2011)
65. Kim ES, "A survey of communityassociated methicillin-resistant Staphylococcus aureus in Korea", J Antimicrob Chemother, 60, pp.1108~1114 (2007)
66. 박지혜, "지난 11년간 5년 간격으로 살펴본 피부과 외래 환자의 피부 세균 감염의 변화 추세", 대한피부과학회지, 47(6), pp.690~695 (2009), 대한피부과학회
67. 이민우, "국내 세 개 대학 병원에서 괴사성 근막염의 특징", 대한내과학회지, 70(6), pp.681~687 (2006), 대한내과학회
68. 송상준, "하지에 발생한 I,II형 급성 괴사성 근막염", 대한정형외과학회지, 42(5), pp.636~643 (2007), 대한정형외과학회
69. Bilton BD, "Aggressive surgical management of necrotizing fasciitis serves to decrease mortality: a retrospective study", Am Surg, 64, pp.397~400 (1998)
70. Dworkin MS, "The epidemiology of necrotizing fasciitis including factors associated with death and amputation", Epidemiol Infect, 137, pp.1609~1614 (2009)
71. Khanna AK, "A case series describing 118 patients with lower limb necrotizing fasciitis", Int J Low Extrem Wounds, 8, pp.112~116 (2009)
72. Luca-Harari B, "Clinical and epidemiological aspects of invasive Streptococcus pyogenes infections in Denmark during 2003 and 2004", J Clin Microbiol, 46, pp.79~86 (2008)
73. Chelsom J, "Necrotising fasciitis due to group A streptococci in western Norway: incidence and clinical features", Lancet, 344, pp.1111~1115 (1994)
74. Lee CY, "Prognostic factors and monomicrobial necrotizing fasciitis: gram-positive versus gram-negative pathogens", BMC Infect Dis, 11, pp.5~ (2011)
75. Childers BJ, "Necrotizing fasciitis: a fourteen-year retrospective study of 163 consecutive patients", Am Surg, 68, pp.109~116 (2002)
76. Brook I, "Clinical and microbiological features of necrotizing fasciitis", J Clin Microbiol, 33, pp.2382~2387 (1995)
77. Ward RG, "Necrotizing fasciitis: 10 years' experience in a district general hospital", Br J Surg, 78, pp.488~489 (1991)
78. Giuliano A, "Bacteriology of necrotizing fasciitis", Am J Surg, 134, pp.52~57 (1977)
79. Salcido RS, "Necrotizing fasciitis: reviewing the causes and treatment strategies", Adv Skin Wound Care, 20, pp.288~293 (2007)
80. Sarani B, "Necrotizing fasciitis: current concepts and review of the literature", J Am Coll Surg, 208, pp.279~288 (2009)
81. McHenry CR, "Determinants of mortality for necrotizing soft-tissue infections", Ann Surg, 221, pp.558~563 (1995)
82. Wong CH, "Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality", J Bone Joint Surg Am, 85-A, pp.1454~1460 (2003)
83. Elliott D, "The microbiology of necrotizing soft tissue infections", Am J Surg, 179, pp.361~366 (2000)
84. Liu YM, "Microbiology and factors affecting mortality in necrotizing fasciitis", J Microbiol Immunol Infect, 38, pp.430~435 (2005)
85. Brothers TE, "Magnetic resonance imaging differentiates between necrotizing and non-necrotizing fasciitis of the lower extremity", J Am Coll Surg, 187, pp.416~421 (1998)
86. Kim KT, "Can Necrotizing Infectious Fasciitis Be Differentiated from Nonnecrotizing Infectious Fasciitis with MR Imaging?", RADIOLOGY, 259(3), pp.816~824 (2011), RADIOLOGICAL SOC NORTH AMERICA
87. Zacharias N, "Diagnosis of necrotizing soft tissue infections by computed tomography", Arch Surg, 145, pp.452~452 (2010)
88. Wong CH, "The LRINEC (laboratory risk indicator for necrotizing fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections", Crit Care Med, 32, pp.1535~1541 (2004)
89. Anaya DA, "Necrotizing soft-tissue infection: diagnosis and management", Clin Infect Dis, 44, pp.705~710 (2007)
90. Mulla ZD, "Invasive group A streptococcal infections in Florida", South Med J, 96, pp.968~973 (2003)
91. Stevens DL, "Antibiotic effects on bacterial viability, toxin production, and host response", Clin Infect Dis, 20(Suppl 2), pp.S154~S157 (1995)
92. Zimbelman J, "Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection", Pediatr Infect Dis J, 18, pp.1096~1100 (1999)
93. Chuang YC, "Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection", Antimicrob Agents Chemother, 42, pp.1319~1322 (1998)
94. Chuang YC, "In vitro synergism between cefotaxime and minocycline against Vibrio vulnificus", Antimicrob Agents Chemother, 41, pp.2214~2217 (1997)
95. Liu JW, "Prognostic factors and antibiotics in Vibrio vulnificus septicemia", Arch Intern Med, 166, pp.2117~2123 (2006)
96. Tang HJ, "In vitro and in vivo activities of newer fluoroquinolones against Vibrio vulnificus", Antimicrob Agents Chemother, 46, pp.3580~3584 (2002)
97. Jallali N, "Hyperbaric oxygen as adjuvant therapy in the management of necrotizing fasciitis", Am J Surg, 189, pp.462~466 (2005)
98. Riseman JA, "Hyperbaric oxygen therapy for necrotizing fasciitis reduces mortality and the need for debridements", Surgery, 108, pp.847~850 (1990)
99. Darenberg J, "Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, Placebocontrolled trial", Clin Infect Dis, 37, pp.333~340 (2003)
100. Kaul R, "Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome: a comparative observational study: the Canadian Streptococcal Study Group", Clin Infect Dis, 28, pp.800~807 (1999)

관련 논문AI추천